Mallika Sachdev Dhawan MD
Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology
Medical Director, Genentech, gRED
Join to View Full Profile
1825 4th StSan Francisco, CA 94143
Dr. Dhawan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2014 - 2017
Duke University HospitalResidency, Internal Medicine, 2011 - 2014
University of California San Diego School of MedicineClass of 2011
University of California, San DiegoB.S., Bioengineering, Magna Cum Laude, 2002 - 2006
Certifications & Licensure
CA State Medical License 2014 - 2026
NC State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Rosenberg Prostate Cancer Research Fellow 2017
- Sean Quinlan Career Development Award 2016
- Simon Strauss Foundation Cancer Center Award 2015
- Join now to see all
Clinical Trials
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Start of enrollment: 2020 Jun 18
Publications & Presentations
PubMed
- 1 citationsUpdated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.Erica S Tsang, Rahul R Aggarwal, Emily K Bergsland, Susan Calabrese, Alexandrine Rozie
JCO Precision Oncology. 2024-11-01 - Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal
Clinical Cancer Research. 2024-10-15 - Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.Erica S Tsang, Mallika S Dhawan, Romain Pacaud, Scott Thomas, Jennifer Grabowsky
JCO Precision Oncology. 2024-06-01
External Links
- UCSF profilehttp://profiles.ucsf.edu/mallika.dhawan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
